References
- Gertz M A, Lacy M Q, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 2004; 18: 17–37
- Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette J C, Ronco P, Quet F, Cogne M, Fermand J P. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083–1093
- Ishikawa I, Chikazawa Y, Sato K, Nakagawa M, Imamura H, Hayama S, Yamaya H, Asaka M, Tomosugi N, Yokoyama H, Matsumoto K. Proteomic analysis of serum, outflow dialysate and adsorbed protein onto dialysis membranes (polysulfone and pmma) during hemodialysis treatment using SELDI-TOF-MS. Am J Nephrol 2006; 26: 372–380
- Hutchison C A, Cockwell P, Reid S, Chandler K, Mead G P, Harrison J, Hattersley J, Evans N D, Chappell M J, Cook M, Goehl H, Storr M, Bradwell A R. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007; 18: 886–895